Literature DB >> 34421499

Building the Future Therapies for Down Syndrome: The Third International Conference of the T21 Research Society.

Mara Dierssen1,2,3, Yann Herault4, Pablo Helguera5, Maria Martínez de Lagran1,3, Anna Vazquez2, Bradley Christian6, Maria Carmona-Iragui7,8, Frances Wiseman9, William Mobley10, Elizabeth M C Fisher11, Veronique Brault4, Anna Esbensen12, Lisa M Jacola13, Marie Claude Potier14, Eric D Hamlett15, Leonard Abbeduto16, Laura Del Hoyo Soriano16, Jorge Busciglio17, Maria Florencia Iulita18, John Crispino19, Sébastien Malinge20, Eugenio Barone21, Marzia Perluigi21, Floriana Costanzo22, Jean Maurice Delabar14, Renata Bartesaghi23, Alain D Dekker24, Peter De Deyn24,25, Juan Fortea Ormaechea7,8, Patricia A Shaw26, Tarik F Haydar26, Stephanie L Sherman27, André Strydom28, Anita Bhattacharyya6.   

Abstract

Research focused on Down syndrome has increased in the last several years to advance understanding of the consequences of trisomy 21 (T21) on molecular and cellular processes and, ultimately, on individuals with Down syndrome. The Trisomy 21 Research Society (T21RS) is the premier scientific organization for researchers and clinicians studying Down syndrome. The Third International Conference of T21RS, held June 6-9, 2019, in Barcelona, Spain, brought together 429 scientists, families, and industry representatives to share the latest discoveries on underlying cellular and molecular mechanisms of T21, define cognitive and behavioral challenges and better understand comorbidities associated with Down syndrome, including Alzheimer's disease and leukemia. Presentation of cutting-edge results in neuroscience, neurology, model systems, psychology, cancer, biomarkers and molecular and phar-ma-cological therapeutic approaches demonstrate the compelling interest and continuing advancement in all aspects of understanding and ameliorating conditions associated with T21.
Copyright © 2021 by S. Karger AG, Basel.

Entities:  

Keywords:  Alzheimer's disease; Biomarkers; Down syndrome; Intellectual disability; Language impairment; Mouse models; Neurodevelopmental disorders; Trisomy 21 Research Society

Year:  2021        PMID: 34421499      PMCID: PMC8339505          DOI: 10.1159/000514437

Source DB:  PubMed          Journal:  Mol Syndromol        ISSN: 1661-8769


  48 in total

1.  Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society.

Authors:  Roger H Reeves; Jean Delabar; Marie-Claude Potier; Anita Bhattacharyya; Elizabeth Head; Cynthia Lemere; Alain D Dekker; Peter De Deyn; Pablo Caviedes; Mara Dierssen; Jorge Busciglio
Journal:  Mol Syndromol       Date:  2018-10-30

Review 2.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

3.  Gamma frequency entrainment attenuates amyloid load and modifies microglia.

Authors:  Hannah F Iaccarino; Annabelle C Singer; Anthony J Martorell; Andrii Rudenko; Fan Gao; Tyler Z Gillingham; Hansruedi Mathys; Jinsoo Seo; Oleg Kritskiy; Fatema Abdurrob; Chinnakkaruppan Adaikkan; Rebecca G Canter; Richard Rueda; Emery N Brown; Edward S Boyden; Li-Huei Tsai
Journal:  Nature       Date:  2016-12-07       Impact factor: 49.962

4.  The Prevalence of OSA Among an Adult Population With Down Syndrome Referred to a Medical Clinic.

Authors:  Michelle Cornacchia; Janis Sethness; Philip Alapat; Yu-Hsiang Lin; Cynthia Peacock
Journal:  Am J Intellect Dev Disabil       Date:  2019-01

5.  Down Syndrome Critical Region 1 Gene, Rcan1, Helps Maintain a More Fused Mitochondrial Network.

Authors:  Valentina Parra; Francisco Altamirano; Carolina P Hernández-Fuentes; Dan Tong; Victoriia Kyrychenko; David Rotter; Zully Pedrozo; Joseph A Hill; Verónica Eisner; Sergio Lavandero; Jay W Schneider; Beverly A Rothermel
Journal:  Circ Res       Date:  2018-01-23       Impact factor: 17.367

Review 6.  Alzheimer's disease in Down syndrome: An overlooked population for prevention trials.

Authors:  André Strydom; Antonia Coppus; Rafael Blesa; Adrian Danek; Juan Fortea; John Hardy; Johannes Levin; Georg Nuebling; Anne-Sophie Rebillat; Craig Ritchie; Cornelia van Duijn; Shahid Zaman; Henrik Zetterberg
Journal:  Alzheimers Dement (N Y)       Date:  2018-12-13

Review 7.  A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome.

Authors:  Frances K Wiseman; Tamara Al-Janabi; John Hardy; Annette Karmiloff-Smith; Dean Nizetic; Victor L J Tybulewicz; Elizabeth M C Fisher; André Strydom
Journal:  Nat Rev Neurosci       Date:  2015-08-05       Impact factor: 34.870

Review 8.  Down Syndrome Is a Metabolic Disease: Altered Insulin Signaling Mediates Peripheral and Brain Dysfunctions.

Authors:  Mara Dierssen; Marta Fructuoso; María Martínez de Lagrán; Marzia Perluigi; Eugenio Barone
Journal:  Front Neurosci       Date:  2020-07-08       Impact factor: 4.677

9.  Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors.

Authors:  Rani K Powers; Rachel Culp-Hill; Michael P Ludwig; Keith P Smith; Katherine A Waugh; Ross Minter; Kathryn D Tuttle; Hannah C Lewis; Angela L Rachubinski; Ross E Granrath; María Carmona-Iragui; Rebecca B Wilkerson; Darcy E Kahn; Molishree Joshi; Alberto Lleó; Rafael Blesa; Juan Fortea; Angelo D'Alessandro; James C Costello; Kelly D Sullivan; Joaquin M Espinosa
Journal:  Nat Commun       Date:  2019-10-18       Impact factor: 14.919

10.  Inhibitory designer receptors aggravate memory loss in a mouse model of down syndrome.

Authors:  Eric D Hamlett; Aurélie Ledreux; Anah Gilmore; Elena M Vazey; Gary Aston-Jones; Heather A Boger; Daniel Paredes; Ann-Charlotte E Granholm
Journal:  Neurobiol Dis       Date:  2019-10-31       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.